PDB62 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN JAPAN BASED ON RESULTS FROM THE SUBGROUP ANALYSIS OF ASIAN PATIENTS IN THE EMPA-REG OUTCOME TRIAL
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.767
https://www.valueinhealthjournal.com/article/S1098-3015(18)34067-1/fulltext
Title :
PDB62 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN JAPAN BASED ON RESULTS FROM THE SUBGROUP ANALYSIS OF ASIAN PATIENTS IN THE EMPA-REG OUTCOME TRIAL
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)34067-1&doi=10.1016/j.jval.2018.09.767
First page :
Section Title :
Open access? :
No
Section Order :
164